Mesoblast Reports Strong Ryoncil® Sales, Eyes Expansion in Chronic Pain and Heart Failure
Event summary
- Mesoblast reported H1 FY2026 revenue of US$51.3 million, up from US$3.2 million, driven by Ryoncil® sales.
- Ryoncil® generated gross sales of US$57.0 million with a gross profit of US$44.2 million.
- Company secured a US$125.0 million five-year credit-line facility, with US$50.0 million available until June 30, 2026.
- Mesoblast anticipates full-year fiscal 2026 Ryoncil® net revenue to range between US$110 million and US$120 million.
- Phase 3 trial for chronic discogenic low back pain (CLBP) on track to complete 300-patient enrollment target in March/April 2026.
The big picture
Mesoblast's strong financial performance in H1 FY2026 underscores the successful commercial launch of Ryoncil®, positioning the company for further growth in the cellular medicines sector. The strategic focus on expanding indications for Ryoncil® and advancing rexlemestrocel-L through clinical trials aligns with broader industry trends toward targeted therapies for inflammatory diseases. The company's ability to secure non-dilutive financing and maintain financial discipline will be critical as it navigates regulatory and commercial milestones.
What we're watching
- Regulatory Approval
- Whether Mesoblast can secure full FDA approval for rexlemestrocel-L in end-stage heart failure patients with LVADs.
- Market Expansion
- The pace at which Mesoblast can expand Ryoncil® coverage to additional transplant centers and indications.
- Financial Performance
- How Mesoblast will manage its net operating cash spend and maintain positive cash flow from Ryoncil® sales.
Related topics